PHATHOM PHARMACEUTICALS, INC. (PHAT) News

PHATHOM PHARMACEUTICALS, INC. (PHAT): $10.03

0.01 (+0.10%)

POWR Rating

Component Grades

Momentum

C

Stability

F

Sentiment

Quality

F

Add PHAT to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#359 of 362

in industry

Filter PHAT News Items

PHAT News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

PHAT News Highlights

  • PHAT's 30 day story count now stands at 3.
  • Over the past 8 days, the trend for PHAT's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • DEC and DRUG are the most mentioned tickers in articles about PHAT.

Latest PHAT News From Around the Web

Below are the latest news stories about PHATHOM PHARMACEUTICALS INC that investors may wish to consider to help them evaluate PHAT as an investment opportunity.

Phathom Pharmaceuticals Announces Expansion of Existing Loan and Security Agreement with Hercules Capital

Amendment provides more favorable terms including a 14-month extension of the interest-only period and maturity date until December 2027Up to an additional $100 million in non-dilutive capital available subject to the achievement of certain revenue milestonesCash runway now expected through the end of 2026 FLORHAM PARK, N.J., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for g

Yahoo | December 14, 2023

Several Insiders Invested In Phathom Pharmaceuticals Flagging Positive News

Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...

Yahoo | December 14, 2023

Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD

New drug application (NDA) seeks U.S. Food and Drug Administration (FDA) approval for VOQUEZNA® as a daily treatment for heartburn associated with Non-Erosive GERD, the largest subcategory of GERDJuly 19, 2024 PDUFA target action date assigned by the FDA FLORHAM PARK, N.J., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the FDA has

Yahoo | December 6, 2023

Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn

VOQUEZNA, the first and only FDA-approved potassium-competitive acid blocker (PCAB), is now available through major retail pharmacies and BlinkRx, an end-to-end digital fulfillment channelVOQUEZNA tablets in 30-count bottles are now commercially available for the healing and maintenance of healing of all severities of Erosive GERD, and relief of heartburn associated with Erosive GERD1 FLORHAM PARK, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmac

Yahoo | November 28, 2023

Phathom Pharmaceuticals Inc (PHAT) Reports Q3 2023 Financial Results

Key Takeaways from the Third Quarter Earnings Report

Yahoo | November 9, 2023

Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates

VOQUEZNA® (vonoprazan) tablets approved by the U.S. Food and Drug Administration (FDA) for the treatment of Erosive GERD and relief of associated heartburn in adults, marking the first major innovation in the U.S. Erosive GERD market in over 30 yearsCommercial availability of VOQUEZNA for Erosive GERD and H. pylori expected December 2023New Drug Application (NDA) submitted to the FDA for vonoprazan as a once-daily treatment for Non-Erosive GERD, the largest subcategory of GERD FLORHAM PARK, N.J.

Yahoo | November 9, 2023

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults

VOQUEZNA® (vonoprazan) product photos VOQUEZNA® (vonoprazan) 20 mg and 10 mg bottle VOQUEZNA® (vonoprazan) product photos VOQUEZNA® (vonoprazan) 10 mg and 20 mg tablet FDA approval marks the first major innovation to the U.S. Erosive GERD market in over 30 yearsVOQUEZNA® met the primary endpoints and key secondary superiority endpoints in the pivotal Phase 3 PHALCON-EE trial evaluating VOQUEZNA in comparison to a standard-of-care proton pump inhibitor (PPI)1Commercial availability of VOQUEZNA ex

Yahoo | November 1, 2023

Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA® TRIPLE PAK® (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA® DUAL PAK® (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults

Planning for a December 2023 U.S. launch for H. pylori, together with the U.S. launch of vonoprazan for Erosive GERD, if approved FLORHAM PARK, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced that the U.S. Food and Drug Administration (FDA) has approved the Prior Approval Supplement (PAS) for the reformulation of vonoprazan tab

Yahoo | October 30, 2023

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

FLORHAM PARK, N.J., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of its management team are scheduled to participate in the following investor conferences in November: Guggenheim Securities 5th Annual Inflammation, Neurology & Immunology Conference in New York, NYDate: Tuesday, November 7, 2023Live Webcast: 2:30 p.m.

Yahoo | October 25, 2023

Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD

Submission based on positive results from Phase 3 PHALCON-NERD-301 in which vonoprazan 10 mg and 20 mg controlled heartburn symptoms through the entire 6 months of the study with a safety profile consistent with prior vonoprazan studiesNew drug application (NDA) seeks U.S. Food and Drug Administration (FDA) approval for vonoprazan as a daily treatment for Non-Erosive GERD, the largest subcategory of GERD with an estimated U.S. adult population of 38 millionFDA action date for Non-Erosive GERD ND

Yahoo | September 26, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!